Evaluation of Anti-Cancer Activity of Sotagliflozin in HUH-7 Hepatoma Cell Lines and DEN–CCl₄ Model of Hepatocellular Carcinoma in Male Wistar Albino rats

The objective of the study was to evaluate cytotoxic, antioxidant, and anti-cancer effects of Sotagliflozin in Hepatocellular carcinoma (HCC) using suitable in-vitro and in-vivo models. 3-(4,5-dimethylthiazol-2yl)-2,5diphenyltetrazolium bromide (MTT assay) and ferric reducing antioxidant power assay (FRAP) were done to assess the cytotoxic and the antioxidant property of Sotagliflozin on Human hepatoma cells. In MTT assay, a modest reduction in cell viability with Sotagliflozin was observed. In FRAP assay, a dose dependent antioxidant activity of Sotagliflozin was seen. For in vivo study, 27 Wistar rats were randomly assigned to five groups: Normal Control, Cancer Control, Cisplatin (6 mg/kg), Sotagliflozin (10 mg/kg) and Sotagliflozin (20 mg/kg). Body weight, Liver function tests and Alfa-fetoprotein were analysed at baseline, once in 2 weeks and at the end of the study (10th week). At the end of 10 weeks, animals were sacrificed, liver tissues were collected for histopathological analysis and AMPK estimation. Sotagliflozin resulted in favourable changes in LFT & AFP and increased AMPK expression in HCC. Histopathological examination revealed attenuation of HCC features with Sotagliflozin. Hence, Sotagliflozin could be a promising therapeutic modality for HCC, which can be further explored in larger preclinical and clinical studies